Lymphoid blast transformation in an MPN with BCR-JAK2 treated with ruxolitinib: putative mechanisms of resistance.
Chen JA, Hou Y, Roskin KM, Arber DA, Bangs CD, Baughn LB, Cherry AM, Ewalt MD, Fire AZ, Fresard L, Kearney HM, Montgomery SB, Ohgami RS, Pearce KE, Pitel BA, Merker JD, Gotlib J.
Chen JA, et al.
Blood Adv. 2021 Sep 14;5(17):3492-3496. doi: 10.1182/bloodadvances.2020004174.
Blood Adv. 2021.
PMID: 34505882
Free PMC article.